Get started
ADDEX THERAPEUTICSADDEX THERAPEUTICSADDEX THERAPEUTICS

ADDEX THERAPEUTICS

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

APE chart


Full chart

APE upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪10.14 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
0.054 CHF
Net income (FY)
‪−10.56 M‬ CHF
Revenue (FY)
‪1.62 M‬ CHF
Shares float
‪58.48 M‬
Beta (1Y)
0.98

Employees


Employees (FY)
23
Change (1Y)
−1 −4.17%
Revenue / Employee (1Y)
‪70.31 K‬ CHF
Net income / Employee (1Y)
‪−458.97 K‬ CHF

About ADDEX N


Sector
Health Technology
CEO
Timothy Dyer
Headquarters
Geneva
Website
addextherapeutics.com
Founded
2002
ISIN
CH0029850754
FIGI
BBG006M6ZCZ5
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

APE news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of APE is 0.055 CHF — it has decreased by −3.51% in the past 24 hours. Watch ADDEX THERAPEUTICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ADDEX THERAPEUTICS stocks are traded under the ticker APE.
APE stock has fallen by −3.51% compared to the previous week, the month change is a −6.78% fall, over the last year ADDEX THERAPEUTICS has showed a 30.95% increase.
We've gathered analysts' opinions on ADDEX THERAPEUTICS future price: according to them, APE price has a max estimate of 0.21 CHF and a min estimate of 0.21 CHF. Watch APE chart and read a more detailed ADDEX THERAPEUTICS stock forecast: see what analysts think of ADDEX THERAPEUTICS and suggest that you do with its stocks.
APE reached its all-time high on Sep 7, 2021 with the price of 1.594 CHF, and its all-time low was 0.042 CHF and was reached on Dec 14, 2023. View more price dynamics on APE chart.
See other stocks reaching their highest and lowest prices.
APE stock is 3.64% volatile and has beta coefficient of 0.98. Track ADDEX THERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is ADDEX THERAPEUTICS there?
Today ADDEX THERAPEUTICS has the market capitalization of ‪5.41 M‬, it has decreased by −5.56% over the last week.
Yes, you can track ADDEX THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
ADDEX THERAPEUTICS is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
APE earnings for the last quarter are −0.02 CHF per share, whereas the estimation was −0.01 CHF resulting in a −100.00% surprise. The estimated earnings for the next quarter are −0.01 CHF per share. See more details about ADDEX THERAPEUTICS earnings.
ADDEX THERAPEUTICS revenue for the last quarter amounts to ‪59.00 K‬ CHF, despite the estimated figure of ‪100.00 K‬ CHF. In the next quarter, revenue is expected to reach ‪100.00 K‬ CHF.
APE net income for the last quarter is ‪−1.53 M‬ CHF, while the quarter before that showed ‪12.88 M‬ CHF of net income which accounts for −111.88% change. Track more ADDEX THERAPEUTICS financial stats to get the full picture.
No, APE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 23.00 employees. See our rating of the largest employees — is ADDEX THERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADDEX THERAPEUTICS EBITDA is ‪−4.74 M‬ CHF, and current EBITDA margin is −618.68%. See more stats in ADDEX THERAPEUTICS financial statements.
Like other stocks, APE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADDEX THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADDEX THERAPEUTICS technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADDEX THERAPEUTICS stock shows the sell signal. See more of ADDEX THERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.